

ORIGINAL RESEARCH

Impact of respiratory muscle training on respiratory muscle strength, respiratory function and quality of life in individuals with tetraplegia: a randomised clinical trial

Claire L Boswell-Ruys ^{1,2,3}, Chaminda R H Lewis,^{1,2,3} Nirupama S Wijesuriya,¹ Rachel A McBain,¹ Bonsan Bonne Lee,^{1,2,3} David K McKenzie,^{2,3} Simon C Gandevia,^{1,2,3} Jane E Butler^{1,3}

¹Neuroscience Research
Australia, Sydney, New South
Wales, Australia

²Prince of Wales Hospital and
Community Health Services,
Sydney, New South Wales,
Australia

³University of New South Wales,
Sydney, New South Wales,
Australia

Correspondence to

Dr Claire L Boswell-Ruys,
Neuroscience Research
Australia, Randwick, Sydney,
New South Wales, Australia;
c.boswell-ruys@neura.edu.au

CLB-R and CRHL are joint first
authors.

Received 9 August 2019
Revised 5 December 2019
Accepted 8 December 2019
Published Online First
14 January 2020

ABSTRACT

Background Respiratory complications remain a leading cause of morbidity and mortality in people with acute and chronic tetraplegia. Respiratory muscle weakness following spinal cord injury-induced tetraplegia impairs lung function and the ability to cough. In particular, inspiratory muscle strength has been identified as the best predictor of the likelihood of developing pneumonia in individuals with tetraplegia. We hypothesised that 6 weeks of progressive respiratory muscle training (RMT) increases respiratory muscle strength with improvements in lung function, quality of life and respiratory health.

Methods Sixty-two adults with tetraplegia participated in a double-blind randomised controlled trial. Active or sham RMT was performed twice daily for 6 weeks. Inspiratory muscle strength, measured as maximal inspiratory pressure (P_{Imax}) was the primary outcome. Secondary outcomes included lung function, quality of life and respiratory health. Between-group comparisons were obtained with linear models adjusting for baseline values of the outcomes.

Results After 6 weeks, there was a greater improvement in P_{Imax} in the active group than in the sham group (mean difference 11.5 cmH₂O (95% CI 5.6 to 17.4), $p < 0.001$) and respiratory symptoms were reduced (St George Respiratory Questionnaire mean difference 10.3 points (0.01–20.65), $p = 0.046$). Significant improvements were observed in quality of life (EuroQol-Five Dimensional Visual Analogue Scale 14.9 points (1.9–27.9), $p = 0.023$) and perceived breathlessness (Borg score 0.64 (0.11–1.17), $p = 0.021$). There were no significant improvements in other measures of respiratory function ($p = 0.126$ – 0.979).

Conclusions Progressive RMT increases inspiratory muscle strength in people with tetraplegia, by a magnitude which is likely to be clinically significant. Measurement of baseline P_{Imax} and provision of RMT to at-risk individuals may reduce respiratory complications after tetraplegia.

Trial registration number Australian New Zealand Clinical Trials Registry (ACTRN 12612000929808).

INTRODUCTION

Respiratory muscle weakness following spinal cord injury-induced tetraplegia has profound consequences. First, impairment of the inspiratory muscles affects ventilation and lung volumes. Second,

Key messages

What is the key question?

- ▶ Does progressive respiratory muscle training increase respiratory muscle strength in people with tetraplegia?

What is the bottom line?

- ▶ Increased respiratory muscle strength could reduce respiratory complications, which are one of the leading causes of morbidity and mortality in people with tetraplegia.

Why read on?

- ▶ Respiratory muscle training can increase muscle strength with consequential physiological effects.

ineffective expiratory muscles impair cough and secretion clearance. As a result, respiratory morbidity for individuals with tetraplegia is high with a lifetime of recurrent respiratory tract infections (2/year/person) that often progress to pneumonia.^{1,2}

After tetraplegia, the highest incidence of mortality occurs in the first year with respiratory causes accounting for 28% of deaths.³ The annual incidence of hospital admissions due to pneumonia and atelectasis are 16% in the first year and 12% at 5 years postinjury.² For those who survive 1 year, tetraplegia has a lifetime cost of \$A9.5 million, much of which is attributed to respiratory-related complications.⁴ Consequently, respiratory muscle weakness is a leading cause of morbidity and mortality in people with tetraplegia.^{1,5}

A common measure of respiratory muscle strength is maximal inspiratory pressure (P_{Imax}) or maximal expiratory pressure (P_{Emax}). P_{Imax} may be a discriminator of pneumonia in individuals with tetraplegia with those below threshold values at increased risk.⁶ Therefore, strengthening the respiratory muscles, in particular the inspiratory muscles would be of significant benefit for people with tetraplegia.

Respiratory muscles are skeletal muscles and studies both in able bodied subjects⁷ and in neuromuscular disorders⁸ have shown that training can



© Author(s) (or their
employer(s)) 2020. No
commercial re-use. See rights
and permissions. Published
by BMJ.

To cite: Boswell-Ruys CL,
Lewis CRH, Wijesuriya NS,
et al. *Thorax*
2020;**75**:279–288.

improve inspiratory and expiratory muscle strength as well as lung function. Volitional training cannot improve the function of completely paralysed muscles. However, training has the potential to strengthen the activation and coordination of those respiratory muscles that are partially paralysed through incomplete injury and also muscles that remain fully innervated. Several techniques of respiratory muscle training (RMT) in people with tetraplegia have been described with the aim to strengthen and improve the endurance of inspiratory and expiratory muscles. These techniques include breathing against abdominal weights,⁹ resistive and threshold loading devices,^{9–15} incentive flow spirometry,¹⁶ positive expiratory pressure devices,¹⁷ glossopharyngeal breathing^{18–19} and singing.²⁰ Although many of these techniques improved lung function, there is no conclusive evidence to support one method over another. A relatively recent Cochrane review concluded that further research was required on the effectiveness of RMT in tetraplegia.²¹ A meta-analysis of randomised controlled trials (RCTs) showed there is potential for training to improve respiratory function. However, previous studies were limited with a majority having low power, inadequate group allocation concealment and/or blinding of participants and assessors. Some studies had very short training programmes with other studies having incomplete data.²²

The aim of the current study was to conduct an RCT with adequate power to assess the effect of RMT, using a low-cost threshold respiratory muscle trainer and a progressive training regimen. We hypothesised that 6 weeks of progressive RMT increases respiratory muscle strength with improvements in lung function, quality of life (QoL) and respiratory health (respiratory symptoms and complications).

METHODS

Study participants

Sixty-two people with tetraplegia were recruited from Prince of Wales Hospital, Sydney, Australia, and from the community. Trial eligibility criteria are outlined in box 1. We certify that all applicable institutional and governmental regulations concerning the ethical use of human volunteers were followed during this research. All participants provided informed written consent with an aid of a family member or independent third party prior to enrolment.

Box 1 Trial eligibility criteria

Inclusion

- ▶ Aged ≥18 years.
- ▶ Spinal cord injury-induced tetraplegia between C4 and C8 with related respiratory deficits.
- ▶ American Spinal Injury Association Impairment Scale grades A, B or C defined by the International Standards for Neurological Classification of Spinal Cord Injury.
- ▶ Medically stable as deemed by treating physician.
- ▶ At least 4 weeks after initial injury date.

Exclusion

- ▶ Mechanically ventilated.
- ▶ Pregnancy.
- ▶ Significant chest trauma such as flail ribs or pneumothorax.
- ▶ Diagnosis of a major coexisting respiratory or neurological illness or a cognitive impairment.

Study design

A single-site randomised double-blind placebo (sham) controlled trial was undertaken.

Randomisation and blinding

A computer-generated adaptive random allocation schedule was created by a person not involved in data collection or recruitment. Participants were allocated to sham or active treatment in a 1:1 ratio (concealed). The allocation algorithm implemented in Stata minimised imbalances in two prognostic factors: American Spinal Injury Association Impairment Scale grade (A and B vs C) and time since injury (<6 months vs >1 year). At completion of each participant's baseline assessment, an allocation request was placed to an independent person who revealed the participant's group allocation. A participant was considered to have entered the trial at this point. Participants, treating therapists and assessors were blinded to the allocated treatment group throughout the trial.

Procedures

All participants performed supervised RMT with a single threshold RMT device (Threshold IMT, Respironics, New Jersey, USA). The sham device was modified to hold the pressure valve permanently open. A ring of tape encircled each device to disguise the valve position. Thus, the sham device was identical in appearance to the active device. All devices had the appearance of the resistance being altered depending on participant respiratory strength, but the sham device resistance did not change. Training followed a non-linear exercise regimen, which increased the training intensity as strength improved. Three to five sets of 12 breaths, separated by quiet breathing for 2 min, were performed twice daily, 5 days a week for 6 weeks. All participants commenced with inspiratory training each session and progressed to expiratory training after 2 min of quiet breathing. Participants inspired from end-tidal volume, through




Figure 1 Participant flow throughout trial duration. RMT, respiratory muscle training.

Table 1 Participant characteristics at baseline

Characteristic	Sham training (n=32)	Active training (n=30)
Age (years)*	55.7±14.9	51.5±14.3
Sex (male : female)	28:4	30:0
Body mass index (kg/m ²)*	25.6±6.3	24.5±5.0
Single neurological level of spinal cord injury, no of participants		
C4	10	11
C5	6	6
C6	8	8
C7	8	5
American Spinal Injury Association Impairment Scale, no of participants		
A (motor complete)	16	16
B (motor complete)	4	5
C (motor incomplete)	12	9
No of participants		
Acute (<6 months)	15	15
Chronic (>1 year)	17	15
Time since injury		
Acute (<6 months) in days	92.5±43.4	83.8±47.7
Chronic (>1 year) in years	23.1±15.6	25.4±13.0
Lung function measures*		
Maximal inspiratory pressure (cmH ₂ O)	51.5±19.7	48.4±22.6
Maximal expiratory pressure (cmH ₂ O)	33.2±14.0	32.8±18.2
Vital capacity (L)	2.7±0.9	2.4±0.9
Inspiratory capacity (L)	2.1±0.7	2.0±0.7
Peak expiratory cough flow (L/s)	4.7±1.6	4.6±1.5
FEV ₁ (L/s)	1.8±0.7	1.9±0.8
FVC (L/s)	2.4±1.0	2.5±1.0
Total lung capacity (L)	4.9±1.2	5.0±1.2
Quality of life: SF-36ww† score/100		
Physical functioning	30 (0–70)	30 (15–75)
Role limitations (physical health)	25 (0–100)	50 (0–100)
Role limitations (emotional problems)	100 (17–100)	100 (67–100)
Energy/fatigue	55 (30–73)	50 (35–70)
Emotional well-being	76 (58–92)	80 (60–84)
Social functioning	50 (13–75)	75 (50–88)
Pain	68 (40–80)	48 (38–68)
General health	60 (25–73)	45 (25–70)
Quality of life: EQ-5D VAS	55 (40–74)	60 (48–71)
Perceived breathlessness (Borg)*(score/10)		
At rest	0.8±1.0	0.8±1.1
During 10 inspiratory loaded breaths at 15 cmH ₂ O	3.4±2.0	2.9±2.1
During 10 expiratory loaded breaths at 15 cmH ₂ O	4.3±2.4	3.4±1.7
St George Respiratory Questionnaire†		
Symptoms score	21.6 (0.0–36.2)	24.7 (11.1–37.5)
Activity score	0.0 (0.0–20.3)	6.8 (0.0–28.4)

Continued

Table 1 Continued

Characteristic	Sham training (n=32)	Active training (n=30)
Impacts score	12.4 (5.2–25.1)	12.2 (1.2–27.0)
Total score	13.5 (6.0–20.3)	11.0 (3.9–29.5)

*Mean±SD.

†Median (IQR).

EQ-5D VAS, EuroQol-Five Dimensional Visual Analogue Scale; SF-36ww, Short Form Health Survey: walk/wheel.

a mouthpiece attached to the inspiratory end of the device, and the resistance was set initially to 30% of each participant's baseline P_{Imax}. This setting was subsequently increased each week by 10% weekly measured P_{Imax} if tolerated (capped at 80% weekly measured P_{Imax}), otherwise the resistance was increased by 5%. The protocol for expiratory training was identical except that participants exhaled through the opposite end of the same device from total lung capacity (TLC). The expiratory resistance was set at 30% baseline P_{Emax} and increased each week as above. The training intensity, duration and frequency were based on limb muscle protocols and protocols used to effectively train respiratory muscles in patients with chronic obstructive pulmonary disease and motoneurone disease.^{8, 23} Tolerance to the training was measured using the Modified Borg score for 'difficulty to breathe through the device', participant score of 'severe' (5) or greater was considered as non-tolerance.

Outcomes

The apriori primary outcome was inspiratory muscle strength at 6 weeks, indicated by P_{Imax} adjusted for pretraining P_{Imax}, between the active and sham training groups. Voluntary P_{Imax} was measured at functional residual capacity (FRC) using a portable lung function machine (Hyp'air, Belgium) according to American Thoracic Society guidelines. Secondary outcomes of lung function included measures of inspiratory capacity (IC), vital capacity (VC), FVC, FEV₁, peak expiratory flow while coughing (PEF_c), TLC and P_{Emax} at TLC. A minimum of three attempts of each measure was made, within 5% error, and the best performance recorded for analysis. Perceived breathlessness was rated at rest and during respiratory loading (15 cmH₂O) using the Modified Borg Scale. Respiratory-related morbidity was recorded as the number of respiratory infections (verified by participant's medical practitioner) and infections requiring hospitalisation (verified by radiological evidence) within 1 year after the completion of the intervention. Respiratory health was assessed by the St George Respiratory Questionnaire (SGRQ).²⁴ QoL was measured using the Short Form Health Survey: walk/wheel (SF-36ww) validated for people with SCI²⁵ and the EuroQol-Five Dimensional Visual Analogue Scale (EQ-5D VAS).²⁶ All measures were made at baseline, 6 weeks and 1 year. At the completion of the 1-year follow-up, participants were given a new unaltered device to continue training, but were not told their group allocation.

Statistical analysis

A minimum of 32 participants per group was calculated apriori to be sufficient to detect a clinically meaningful improvement (on the advice of respiratory staff specialists) of a between-group difference of 10 cmH₂O in the primary outcome measure at 6 weeks. Recruitment of 80 participants would allow for an estimated 20% dropout. Power calculations were based on published data where baseline P_{Imax} ranged from 40 to 63

Table 2 Respiratory muscle training parameters per group allocation after 6 weeks

Training	All data (N=62)			Acute (n=30)			Chronic (n=32)		
	Sham	Active	P value	Sham	Active	P value	Sham	Active	P value
Inspiratory muscle training									
Baseline pressure (cmH ₂ O)*	3.6±0.0	14.4±5.5	<0.001	3.6±0.0	14.3±4.7	<0.001	3.6±0.0	14.6±6.4	<0.001
Percentage of initial PImax	8.3±0.0	31.4±0.1	<0.001	7.6±0.0	29.7±0.0	<0.001	8.9±0.0	33.0±0.1	<0.001
Maximum training pressure (cmH ₂ O)*	4.6±5.6	33.8±8.3	<0.001	5.7±8.1	33.1±7.8	<0.001	3.6±0.0	34.4±9.0	<0.001
Percentage of initial PImax	9.9±0.1	79.8±0.3	<0.001	11.0±0.1	73.3±0.3	<0.001	8.9±0.0	86.2±0.4	<0.001
Average training pressure (cmH ₂ O)*	3.7±0.4	26.9±7.6	<0.001	3.8±0.6	25.7±6.9	<0.001	3.6±0.0	28.1±8.4	<0.001
Percentage of initial PImax	8.4±0.0	61.7±0.2	<0.001	7.9±0.0	55.4±0.2	<0.001	8.9±0.0	67.9±0.2	<0.001
Training sets per session	4.1±0.7	4.2±0.6	0.549	3.9±0.7	4.1±0.6	0.408	4.3±0.6	4.2±0.6	0.641
Inspiratory work (sets × pressure, cmH ₂ O)	9.5±3.2	77.3±34.5	<0.001	8.3±3.4	67.9±29.0	<0.001	10.6±2.7	86.8±37.8	<0.001
Borg score per session (/10)	1.7±1.4	3.6±1.1	<0.001	2.1±1.3	3.5±0.9	0.002	1.4±1.3	3.6±1.2	<0.001
Expiratory muscle training									
Baseline pressure (cmH ₂ O)*	3.6±0.0	11.8±4.7	<0.001	3.6±0.0	13.0±5.8	<0.001	3.6±0.0	10.6±2.9	<0.001
Percentage of initial PEmax	13.4±0.1	40.4±0.1	<0.001	10.7±0.0	37.0±0.1	<0.001	15.8±0.1	43.9±0.2	<0.001
Maximum training pressure (cmH ₂ O)*	3.6±0.0	23.9±7.8	<0.001	3.6±0.0	24.5±8.9	<0.001	3.6±0.0	23.3±6.8	<0.001
Percentage of initial PEmax	13.4±0.1	82.8±0.3	<0.001	10.7±0.0	72.0±0.2	<0.001	15.8±0.1	93.6±0.3	<0.001
Average training pressure (cmH ₂ O)*	3.6±0.0	18.8±6.4	<0.001	3.6±0.0	19.8±7.8	<0.001	3.6±0.0	17.9±4.7	<0.001
Percentage of initial PEmax	13.4±0.1	64.6±0.2	<0.001	10.7±0.0	57.0±0.1	<0.001	15.8±0.1	72.2±0.2	<0.001
Training sets per session	4.1±0.7	4.1±0.6	1.000	3.9±0.7	4.0±0.6	0.678	4.2±0.6	4.1±0.6	0.641
Expiratory work (sets × pressure, cmH ₂ O)	8.9±3.1	49.3±24.9	<0.001	8.0±3.4	48.4±28.4	<0.001	9.8±2.7	47.0±22.2	<0.001
Borg score per session (/10)	1.9±1.4	3.9±1.1	<0.001	2.3±1.4	3.6±1.0	0.005	1.5±1.3	3.9±1.3	<0.001

All values are mean±SD.

*Actual pressure is not participant perceived pressure. Inspiratory and expiratory work represents an average per training session.

PEmax, maximal expiratory pressure; PImax, maximal inspiratory pressure.

cmH₂O (SD=14 cmH₂O,^{14 16 27} power=0.8, two-tailed α =0.05). A 10 cmH₂O increase in PImax represents a potential 16% to 25% increase in strength reported in the literature, a worthwhile improvement for people with a low PImax.

Data were analysed on an intention-to-treat basis.²⁸ Missing data were deleted on a case-wise basis. Primary outcome data and lung function measures were analysed with analysis of covariance, adjusting for the baseline measures with a linear regression approach. We conducted a sensitivity analysis on the primary analysis to determine if the findings were sensitive to parametric assumptions and CIs were estimated using non-parametric bootstrapping (1000 bootstrap replicates). The treatment effect size was estimated with the between-group mean difference and 95% CIs. Data from the questionnaires were analysed using t-tests and categorical data were analysed using χ^2 or Fisher's exact tests. P values <0.05 were considered statistically significant.

RESULTS

Sixty-two people with tetraplegia were recruited between November 2013 and November 2016 (1-year follow-up ceased in December 2017), [figure 1](#) shows participant flow. Baseline characteristics were well matched between groups ([table 1](#)). The training protocol was adhered to by all participants, a median of 4.1 sets of 12 breaths were performed twice daily (IQR 3.8–4.5) for 6 weeks. There was no difference between the groups in RMT frequency ([table 2](#)). There were no reported adverse events over the course of this trial.

The sham device generated pressures between 1 and 7.7 cmH₂O during inspiration and between 1 and 5.3 cmH₂O during expiration, with corresponding flow rates between 0.5 and 2 L/s. Using the mid-flow rate (1.25 L/s) as representative, the pressure generated during inspiration and expiration was 3.6 cmH₂O with a mean resistance of 4.1 cmH₂O/L/s, linear across the flow

range. The mean baseline, maximum and average RMT pressures were different, and the active group were trained at significantly higher pressures than the sham group ([table 2](#)). The mean work performed and corresponding Borg scores were different, and the active group had significantly higher values than the sham group ([table 2](#)). During the 6 weeks, the training intensity of the active group (measured as percentage of initial pressures) increased at a decreasing rate and stabilised after ~4 weeks ([figure 2](#)).

Primary outcome

After 6 weeks of RMT, PImax was significantly greater in the active group compared with the sham group ([table 3](#)). The mean between-group difference for all participants was 11.5 cmH₂O




Figure 2 Mean respiratory muscle training (RMT) intensity (±SD) per week represented as percentage of initial maximal inspiratory pressure or initial maximal expiratory pressure.

Table 3 Outcome measures at baseline, after 6 weeks of RMT and after 1 year of unsupervised training

	Sham RMT group			Active RMT group			P value at 6 weeks	P value at 1 year
	Baseline (n=32)	6 weeks (n=31)	1 year (n)*	Baseline (n=30)	6 weeks (n=29)	1 year (n)*		
Primary outcome								
Plmax (cmH ₂ O)	51.5±19.7	54.9±21.3	63.0±29.0 (15)	48.4±22.6	63.7±24.0	70.2±32.2 (19)	<0.001	0.081
Secondary outcomes								
PEmax (cmH ₂ O)	33.2±14.0	37.4±17.8	36.2±16.5 (15)	32.8±18.2	38.4±21.7	44.6±20.5 (18)	0.799	0.075
Lung function								
FEV ₁ (L)	1.9±0.7	1.9±0.8	2.0±1.0 (16)	1.8±0.8	1.8±0.8	2.1±0.8 (19)	0.385	0.674
FVC (L)	2.5±0.9	2.6±1.0	2.9±1.4 (16)	2.3±1.0	2.5±1.1	2.8±1.0 (19)	0.349	0.600
Inspiratory capacity (L)	2.1±0.7	2.1±0.8	1.6±0.7 (7)	2.0±0.7	2.0±0.8	2.2±0.5 (11)	0.979	0.077
PEFc (L/s)	4.6±1.6	4.7±1.8	4.2±1.8 (8)	4.6±1.5	4.7±1.6	5.4±1.8 (11)	0.893	0.659
Vital capacity (L)	2.6±0.9	2.7±1.1	2.8±1.4 (7)	2.3±0.8	2.5±1.0	3.0±0.9 (11)	0.126	0.391
Total lung capacity (L)	4.8±1.3	4.9±1.2	4.3±1.8 (4)	5.0±1.1	5.1±1.3	5.0±1.0 (7)	0.402	0.689
Respiratory complications (n)	0	6	10 (19)†	0	2	3 (22)†	0.257	0.017
Quality of life: Short Form-36 (SF-36ww)								
Physical functioning	36.4±34.9	41.6±38.1	41.9±29.3*	38.0±32.2	54.0±32.8	44.9±28.4*	0.426	0.761
Role limitations (physical)	38.2±43.4	57.8±46.3	46.2±43.1	50.0±41.2	75.0±39.5	68.1±42.7	0.824	0.759
Role limitations (emotional)	68.6±44.9	75.0±41.3	79.5±34.9	73.4±36.1	89.8±21.0	72.2±40.0	0.865	0.629
Energy/fatigue	50.0±21.9	51.1±22.6	59.2±17.8	53.0±19.4	56.2±27.9	54.7±21.3	0.763	0.994
Emotional well-being	74.8±17.3	73.0±26.1	78.2±7.8	74.1±17.2	70.1±19.6	72.4±16.4	0.801	0.899
Social functioning	50.8±36.8	68.1±30.6	64.6±28.8	67.7±26.2	75.2±31.7	64.1±31.8	0.398	0.200
Pain	60.3±26.8	71.9±24.6	79.5±23.3	53.9±22.6	58.2±28.9	62.7±29.7	0.419	0.946
General health	53.8±26.4	60.3±27.0	56.5±24.0	51.3±23.6	60.4±28.5	56.1±20.4	0.991	0.986
Quality of life: EQ-5D VAS	54.8±22.9	63.5±21.1	68.1±15.2	58.7±21.4	68.9±22.3	59.7±18.2	0.541	0.877
Perceived breathlessness (Borg score)								
At rest	0.8±1.0	0.5±0.7	0.7±0.9*	0.8±1.1	1.0±1.6	1.0±1.6*	0.021	0.313
Inspiratory loaded breaths	3.4±2.0	3.3±2.2	N/A	2.9±2.1	1.7±1.5	N/A	0.049	N/A
Expiratory loaded breaths	4.3±2.4	3.9±2.0	N/A	3.4±1.7	2.5±1.9	N/A	0.494	N/A
SGRQ								
Symptom severity score	21.4±17.5	26.2±23.8	13.9±16.2*	25.2±18.8	20.5±18.7	23.0±19.8*	0.046	0.821
Activity score	9.0±12.0	4.9±7.6	5.7±6.1	13.2±15.6	3.1±5.2	2.7±5.0	0.485	0.765
Impacts score	18.9±18.5	14.7±14.9	15.1±13.3	17.1±18.5	10.9±12.1	10.5±12.1	0.838	0.601
Total score	15.1±12.8	13.3±13.1	11.2±10.5	16.5±15.4	9.9±9.6	9.7±10.0	0.451	0.573

Data shown as mean±SD.

N/A as data for this outcome not collected at this time point.

Bold p values indicate significance at level p<0.05.

*Due to missing values at the 1-year follow-up, the number of data points for each outcome is shown in brackets beside each value for PI_{max}, PE_{max} and lung function measures; SF-36, Borg score and SGRQ all had 13 data points for sham RMT and 18 data points for active RMT at 1-year follow-up.

†Includes number of respiratory complications from initial 6 weeks of training for a 1 year total.

EQ-5D VAS, EuroQol-Five Dimensional Visual Analogue Scale questionnaire; PEF_c, peak expiratory cough flow; PE_{max}, maximal expiratory pressure; PI_{max}, maximal inspiratory pressure; RMT, respiratory muscle training; SF-36ww, Short Form Health Survey: walk/wheel; SGRQ, St George Respiratory Questionnaire.

(95% CI=5.6 to 17.4, p<0.001). The confidence limits from the sensitivity analysis were similar to those in the primary analysis (5.81 to 17.01). Individual and group data at baseline and 6 weeks are shown in figure 3. Compared with mean baseline measures, PI_{max} increased by 31.6% in the active group compared with 6.7% in the sham group. There were significant increases in mean PI_{max} in both acute (difference between groups 12.3 cmH₂O, 95% CI=2.1 to 22.3, p=0.021) and chronic groups (difference between groups 11.2 cmH₂O, 95% CI=3.3 to 19.1, p=0.011) (table 4). There were also increases in mean PI_{max} in the motor-complete (difference between groups 12.3 cmH₂O, 95% CI=4.7 to 20.0, p=0.002) and motor-incomplete groups

(difference between groups 10.8 cmH₂O, 95% CI=-0.06 to 21.7, p=0.051) (table 5). Using predictive modelling calculators developed by Mueller *et al*,²⁹ our mean tetraplegia-predicted PI_{max} for motor-complete tetraplegia are 66% at baseline and 91% after 6 weeks of RMT.

Secondary outcomes

After 6 weeks of training, respiratory symptom severity (SGRQ) score for all participants improved more in the active group compared with the sham group (mean between-group difference 10.3 points, 95% CI 0.01 to 20.65, p=0.046; table 3). The chronic




Figure 3 Maximal inspiratory pressures before and after 6 weeks of RMT for individual participants in the sham group (blue lines, panel A) and the active group (red lines, panel B), the solid squares represent group mean \pm SD. Panel C plots the individual participant changes (open triangle) in maximal inspiratory pressures after 6 weeks of RMT, with mean group change (\pm 95% CI) in the solid triangle.

active group had a lower mean score on the EQ-5D VAS, compared with the chronic sham group (mean between-group difference 14.9, 95% CI 1.9 to 27.9, $p=0.023$; table 4).

Borg scores for breathlessness during 10 inspiratory loaded breaths reduced more in the active group compared with the sham group for all participants (mean between-group difference 0.96, 95% CI 0.01 to 1.91, $p=0.049$; table 3), and for participants with a chronic injury (mean between-group difference -1.92 , 95% CI -0.6 to -3.3 , $p=0.009$; table 4), but not during 10 expiratory loaded breaths. Borg scores at rest were greater in the sham group for all participants (mean between-group difference 0.64, 95% CI 0.11 to 1.17, $p=0.021$; table 3) and for participants with an acute injury (mean between-group difference 0.94, 95% CI 0.2 to 1.8, $p=0.025$; table 4).

There was no significant difference between the sham and active groups in PEmax, lung function, number of respiratory complications, remaining SF-36ww fields and SGRQ domains (table 3), nor when analysed by time since injury (table 4) or degree of injury completeness (table 5). However, there were significant correlations between the change in PImax and the change in IC, VC and PEFc (figure 4). For every 10 cmH₂O improvement in PImax, there was a 140 mL increase in IC (figure 4A), 135 mL increase in VC (figure 4B) and 200 mL/s increase in PEFc (figure 4C).

Outcomes at 1-year follow-up

Comparison of baseline data with that collected after 1 year of unsupervised training showed no significant difference between active and sham groups in any outcome measures (table 3) except for the incidence of respiratory complications. There was a greater total number of respiratory complications during the 1-year follow-up period in the sham group ($n=10$) compared with the active group ($n=3$), $p=0.017$. The self-reported frequency of training and benefits of RMT and barriers that prevented participants from using RMT independently are listed in table 6.

DISCUSSION

This is the first large-scale study to demonstrate conclusively that 6 weeks of daily RMT improves inspiratory muscle strength

in both acute and chronic tetraplegia. As a consequence, respiratory-related morbidity declined and QoL improved.

Inspiratory muscle strength

Six weeks of twice-daily RMT increases inspiratory muscle strength but not expiratory muscle strength in people with tetraplegia. This increase in strength occurred in people with acute and chronic tetraplegia, and regardless of the degree of injury completeness. This is supported by studies where no consistent training paradigms exist between the different study populations.²¹

Retrospective analysis of lung function data identified inspiratory muscle strength as the best predictor of the likelihood to develop pneumonia in individuals with tetraplegia.⁶ The proposed pneumonia risk threshold is based on lesion-specific reference values calculated by predictive modelling using measured absolute respiratory function values.²⁹ For individuals with motor-complete tetraplegia, a PImax less than 115% tetraplegia-predicted have a 50% probability of suffering pneumonia. If PImax is greater than 115%, there is a 94% probability of not contracting pneumonia.⁶ For individuals with motor-incomplete tetraplegia, the threshold is 93.5 cmH₂O. Using the predictive modelling calculator supplied,²⁹ which is specific to an individual's level of lesion and time since injury, the mean baseline PImax in our study for motor-complete tetraplegia are 66% tetraplegia-predicted. Post-RMT, mean PImax increased to 91% tetraplegia-predicted. Our lower than published values may be due to PImax being measured at FRC and seated, compared with residual volume in supine which can return a higher value. Despite our PImax values not reaching proposed thresholds, we did show a reduced pneumonia risk with active RMT, which increased inspiratory muscle strength. The incidence of respiratory complications over the year of our trial was three times greater in the sham group (53%) than the active group (14%). This provides evidence that RMT may reduce respiratory-related morbidity and mortality in tetraplegia.

Between 12 weeks and 1 year post-injury, 23% our participants reported a respiratory complication. However, during the first 6 weeks after injury, Jackson and Groomes³⁰ found that 68% patients with tetraplegia developed a respiratory complication. Our participants were not recruited during this period, thus RMT in this susceptible acute stage of tetraplegia warrants further investigation to determine its effects on respiratory complications, a more important determinant of hospital costs than injury severity.³¹

Quality of life

Daily RMT can affect QoL in people with chronic tetraplegia. Current health status measured via the EQ-5D VAS showed the active group reported 12% improvement compared with no change for the sham group. Recent reviews^{21 22} indicated further research was needed into the effect of RMT on the QoL of people living with tetraplegia. This is the first study to demonstrate that RMT can improve the perceived QoL compared with sham training, although there are many factors that impact QoL over 6 weeks, thus the effect seen here may not be attributable to RMT alone. However, when questioned about current respiratory health via the SGRQ, 56% participants in the active group reported improved respiratory health compared with 27% in the sham group. Similar responses were observed for the participants with acute injuries (60% and 43%, respectively).

Table 4 Outcome measures at baseline and after 6 weeks of RMT for groups divided by time since injury (acute group less than 1 year and chronic group greater than 1 year since injury)

	Acute group					Chronic group				
	Sham RMT		Active RMT		P value	Sham RMT		Active RMT		P value
	Baseline (n=15)	6 weeks (n=14)	Baseline (n=15)	6 weeks (n=15)		Baseline (n=17)	6 weeks (n=16)	Baseline (n=15)	6 weeks (n=13)	
Primary outcome										
Plmax (cmH ₂ O)	54.1±20.7	57.6±22.7	49.2±16.8	65.0±18.3	0.021	49.2±19.1	52.7±20.5	47.6±27.8	62.4±29.4	0.011
Secondary outcomes										
PEmax (cmH ₂ O)	38.2±13.4	45.6±17.8	38.6±22.2	47.2±25.4	0.832	28.8±13.3	30.7±15.1	27.0±11.0	29.0±11.9	0.879
Lung function										
FEV ₁ (L)	2.2±0.8	2.3±0.6	1.8±0.7	1.9±0.8	0.988	1.7±0.6	1.6±0.7	1.7±0.8	1.7±0.9	0.345
FVC (L)	2.9±1.0	3.1±0.9	2.3±1.0	2.6±1.1	0.929	2.2±0.8	2.1±0.8	2.3±1.1	2.3±1.1	0.289
Inspiratory capacity (L)	2.4±0.7	2.4±0.8	2.0±0.7	2.0±0.8	0.809	1.9±0.6	1.8±0.7	2.0±0.7	1.9±0.8	0.907
PEF _c (L/s)	4.8±1.7	5.1±1.9	4.8±1.5	5.0±1.6	0.792	4.5±1.6	4.4±1.7	4.3±1.4	4.4±1.4	0.931
Vital capacity (L)	3.1±0.9	3.1±0.8	2.5±0.8	2.8±1.0	0.563	2.3±0.8	2.3±0.9	2.4±0.7	2.3±1.1	0.160
Total lung capacity (L)	5.1±1.5	5.4±1.0	5.0±0.9	5.4±1.0	0.601	4.6±1.2	4.4±1.2	4.9±1.3	4.7±1.5	0.215
Respiratory complications (n)	0	5	0	2	0.390	0	1	0	2	0.589
Quality of life: Short Form-36 (SF-36vww)										
Physical functioning	N/A	N/A	N/A	N/A	N/A	36.4±34.9	41.6±38.1	38.0±32.2	54.0±32.8	0.426
Role limitations (physical)	N/A	N/A	N/A	N/A	N/A	38.2±43.4	57.8±46.3	50.0±41.2	75.0±39.5	0.824
Role limitations (emotional)	N/A	N/A	N/A	N/A	N/A	68.6±44.9	75.0±41.3	73.4±36.1	89.8±21.0	0.865
Energy/fatigue	N/A	N/A	N/A	N/A	N/A	50.0±21.9	51.1±22.6	53.0±19.4	56.2±27.9	0.763
Emotional well-being	N/A	N/A	N/A	N/A	N/A	74.8±17.3	73.0±26.1	74.1±17.2	70.1±19.6	0.801
Social functioning	N/A	N/A	N/A	N/A	N/A	50.8±36.8	68.1±30.6	67.7±26.2	75.2±31.7	0.398
Pain	N/A	N/A	N/A	N/A	N/A	60.3±26.8	71.9±24.6	53.9±22.6	58.2±28.9	0.419
General health	N/A	N/A	N/A	N/A	N/A	53.8±26.4	60.3±27.0	51.3±23.6	60.4±28.5	0.991
Quality of life: EQ-5D VAS	41.7±18.9	61.8±22.7	59.3±25.0	67.7±24.6	0.282	66.5±20.1	65.0±20.4	58.0±17.9	70.4±20.0	0.023
Perceived breathlessness (Borg score)										
At rest	1.0±1.1	0.4±0.5	0.8±1.2	1.2±1.7	0.025	0.6±0.9	0.5±0.8	0.8±1.1	0.9±1.4	0.340
Loaded inspiratory breaths	3.0±1.6	2.3±1.8	2.4±1.5	1.8±1.5	0.907	3.8±2.2	4.1±2.2	3.3±2.5	1.6±1.6	0.009
Loaded expiratory breaths	4.0±2.2	3.4±2.3	3.0±1.7	2.2±2.0	0.768	4.5±2.6	4.5±2.6	3.7±1.7	2.8±1.8	0.533
St George Respiratory Questionnaire										
Symptom severity score	29.3±15.7	28.5±23.3	20.7±26.2	18.5±17.9	0.272	14.4±16.4	24.3±24.8	17.3±24.3	19.2±23.9	0.136
Activity score	N/A	N/A	N/A	N/A	N/A	9.0±12.0	4.9±7.6	15.6±13.2	5.2±3.1	0.295
Impacts score	N/A	N/A	N/A	N/A	N/A	18.9±18.4	14.7±14.9	18.5±17.1	12.1±10.9	0.671
Total score	N/A	N/A	N/A	N/A	N/A	15.1±12.8	13.3±13.1	15.4±16.4	9.6±9.9	0.328

Data shown as mean±SD.

One-year follow-up data not shown due to small participant numbers in each group.

N/A as data for this outcome not collected for this group due to the majority of the questions being relevant to people only living at home.

Bold p values indicate significance at level p<0.05.

EQ-5D VAS, EuroQol-Five Dimensional Visual Analogue Scale questionnaire; PEF_c, peak expiratory cough flow; P_{Emax}, maximal expiratory pressure; P_{lmax}, maximal inspiratory pressure; RMT, respiratory muscle training; SF-36vww, Short Form Health Survey; walk/wheel.

Respiratory symptoms

Respiratory symptoms in people with tetraplegia declined after 6 weeks of RMT. Currently, there is no validated measure to evaluate respiratory symptom severity in tetraplegia. The SGRQ is a validated measure used for respiratory diseases such as COPD²⁴ and although many domains are not applicable to people with tetraplegia we hypothesised that the symptoms domain may be appropriate. This was measured in all participants and reflected significant improvements after RMT. Previous studies in asthma and COPD indicate that a change of 4 points of the total score of the SGRQ is clinically significant.³² As a 10-point difference between the groups was observed in symptom severity alone in the current study, this domain of the SGRQ may be a way to evaluate respiratory health in tetraplegia. An additional SGRQ question explores current respiratory health, and 58% participants in the active group and 35% participants in the sham group reported improved respiratory health post-training.

Breathlessness

The reduction in Borg scores after RMT also indicates improved symptom severity as it assesses breathlessness or perceived exertion.³³ This improvement was only noted at rest, particularly for people with recent injuries. This reduction supports the commonly held idea that people with tetraplegia have dyspnoea^{21 34} due to the increased load on remaining intact respiratory muscles, thereby increasing the work of breathing.³⁵ Interestingly, the Borg score during inspiratory-loaded breaths was only reduced after RMT in the chronic population, which may indicate that the muscles have adapted to the required increased work of breathing. Thus, the feeling of breathlessness during a respiratory infection could be reduced by RMT in the chronic population. Further investigations are warranted to determine if breathlessness can be ameliorated by RMT with more robust measures of dyspnoea, particularly with different degrees of inspiratory loading.

Table 5 Outcome measures at baseline and after 6 weeks of RMT for groups divided by AIS classification (motor complete group classified as AIS A and B and the motor incomplete group classified as AIS C)

	Motor complete group					Motor incomplete group				
	Sham RMT		Active RMT		P value	Sham RMT		Active RMT		P value
	Baseline (n=20)	6 weeks (n=19)	Baseline (n=21)	6 weeks (n=20)		Baseline (n=12)	6 weeks (n=12)	Baseline (n=9)	6 weeks (n=9)	
Primary outcome										
Plmax (cmH ₂ O)	49.9±18.9	52.8±19.8	42.6±16.5	58.3±22.3	0.002	54.1±21.7	58.3±24.0	62.1±29.4	75.8±24.2	0.051
Secondary outcomes										
PEmax (cmH ₂ O)	26.9±10.3	28.2±11.4	25.0±9.5	28.0±10.5	0.723	43.7±13.4	52.1±16.4	50.9±21.2	61.4±22.9	0.509
Lung function										
FEV ₁ (L)	1.6±0.5	1.6±0.6	1.5±0.6	1.6±0.7	0.447	2.4±0.7	2.4±0.8	2.3±0.9	2.4±0.9	0.648
FVC (L)	2.2±0.8	2.1±0.8	2.0±0.8	2.1±0.9	0.412	3.2±0.8	3.3±0.9	3.0±1.0	3.2±1.1	0.635
Inspiratory capacity (L)	2.0±0.7	1.8±0.7	1.8±0.7	1.9±0.7	0.192	2.3±0.7	2.6±0.8	2.3±0.8	2.3±0.9	0.372
PEFc (L/s)	4.2±1.3	4.2±1.4	3.9±1.0	4.1±1.1	0.832	5.5±1.8	5.6±2.0	6.0±1.2	6.1±1.6	0.915
Vital capacity (L)	2.2±0.8	2.3±0.8	2.1±0.6	2.2±0.9	0.157	3.4±0.7	3.3±0.7	3.1±1.0	3.3±1.1	0.562
Total lung capacity (L)	4.5±1.1	4.4±1.3	4.9±1.1	4.9±1.3	0.317	5.4±1.4	5.6±0.7	5.1±1.1	5.5±1.1	0.994
Respiratory complications (n)	0	3	0	2	0.663	0	3	0	0	0.229
Quality of Life: Short Form-36 (SF-36vww)*										
Physical functioning	43.1±34.8	48.5±38.9	42.7±32.0	59.3±31.1	0.204	N/A	N/A	N/A	N/A	N/A
Role limitations (physical)	37.5±43.6	63.5±44.0	51.9±41.4	77.3±39.5	0.490	N/A	N/A	N/A	N/A	N/A
Role limitations (emotional)	61.9±46.9	71.8±44.8	71.8±38.1	87.9±22.5	0.936	N/A	N/A	N/A	N/A	N/A
Energy/fatigue	50.7±21.3	51.9±22.5	56.5±18.3	63.2±24.0	0.736	N/A	N/A	N/A	N/A	N/A
Emotional well-being	74.0±18.5	72.9±26.0	75.4±18.0	73.4±18.9	0.694	N/A	N/A	N/A	N/A	N/A
Social functioning	48.3±36.3	68.4±30.5	70.4±22.5	82.0±27.5	0.628	N/A	N/A	N/A	N/A	N/A
Pain	59.6±27.4	75.5±22.1	56.6±23.2	62.5±29.5	0.659	N/A	N/A	N/A	N/A	N/A
General health	53.9±25.7	62.3±28.5	54.2±23.5	66.4±26.2	0.878	N/A	N/A	N/A	N/A	N/A
Quality of life: EQ-5D VAS	59.0±23.7	64.2±22.3	56.2±17.8	69.2±22.6	0.099	47.9±20.8	62.5±20.2	64.4±28.4	68.3±22.9	0.308
Perceived breathlessness (Borg score)										
At rest	0.6±0.8	0.5±0.8	0.8±1.2	1.0±1.6	0.190	1.0±1.2	0.3±0.5	0.8±0.9	1.1±1.5	0.072
Loaded inspiratory breaths	3.7±2.2	3.8±2.2	2.9±2.4	1.8±1.5	0.109	3.0±1.6	2.5±2.0	2.9±1.1	1.6±1.5	0.179
Loaded expiratory breaths	4.6±2.6	4.2±1.9	3.5±1.9	3.0±2.1	0.978	3.7±2.0	3.3±2.1	3.0±1.3	1.4±1.0	0.143
St George Respiratory Questionnaire										
Symptom severity score	20.0±16.8	22.9±24.0	18.3±24.8	20.8±20.8	0.190	23.7±19.2	31.5±23.4	21.1±26.3	14.7±19.9	0.163
Activity score	8.2±10.2	5.6±8.2	16.8±13.2	4.5±1.6	0.521	N/A	N/A	N/A	N/A	N/A
Impacts score	19.2±20.0	14.4±16.4	20.0±16.2	7.4±6.4	0.730	N/A	N/A	N/A	N/A	N/A
Total score	15.2±13.9	13.2±14.4	16.6±15.7	7.2±6.6	0.589	N/A	N/A	N/A	N/A	N/A

Data shown as mean±SD.

One-year follow-up data not shown due to small participant numbers in each group.

N/A as data for this outcome was only collected for people with chronic tetraplegia in this group due to the majority of the questions being relevant to people only living at home, resulting in only four participants having complete datasets, insufficient for statistical analysis.

*No data available for the SF-36 in the incomplete group due to only n=5 participants having sustained their injury greater than 1 year prior to enrolment, the complete group has n=14 sham and n=13 active participants.


EQ-5D VAS, EuroQol-Five Dimensional Visual Analogue Scale questionnaire; PEF_c, peak expiratory cough flow; PEmax, maximal expiratory pressure; Plmax, maximal inspiratory pressure; SF36-ww, Short Form Health Survey: walk/wheel.**Figure 4** Change in maximal inspiratory pressure (Plmax) after 6 weeks of respiratory muscle training plotted against change in inspiratory capacity (ΔIC, panel A), vital capacity (ΔVC, panel B) and peak expiratory cough flow (ΔPEF_c, panel C) for individual participants. Blue dots represent participants in sham group and red dots represent participants in active group. Equations, R² and p-values represent all data points.

Table 6 Training frequency of participants over 1 year along with self-reported benefits of RMT and barriers preventing RMT use independently (33 participants completed survey after 1 year)

Training frequency over 1 year	Percentage of participants reported	Self-reported benefits of RMT	Percentage of participants reported	Self-reported barriers to RMT	Percentage of participants reported
Sham group		Helped strengthen muscles	45 (n=15)	Busyness with life/lack of time	27 (n=9)
Daily	0 (n=0)	Breathing is better; more air in lungs	30 (n=10)	Laziness	24 (n=8)
Three times per week	6 (n=2)	Felt better/fresher next day as more air in chest; 'like a tonic'	15 (n=5)	No carer to assist as poor hand function	18 (n=6)
Once per week	3 (n=1)	None	15 (n=5)*	Forgetfulness	18 (n=6)
Randomly	6 (n=2)	Increase awareness of breathing habits	12 (n=4)	None	15 (n=5)†
Never	27 (n=9)	Good exercise	6 (n=2)	Lack of time with carer	12 (n=4)
Active group		Less breathlessness when sitting upright	3 (n=1)	Felt could breathe well enough	12 (n=4)
Daily	6 (n=2)	Less requirement for assisted coughs	3 (n=1)	Not fun sucking on plastic	9 (n=3)
Three times per week	3 (n=1)	Improved ability to talk	3 (n=1)	Too complex	9 (n=3)
Once per week	6 (n=2)	Helped sleep apnoea	3 (n=1)	Misplaced device	6 (n=2)
Randomly	18 (n=6)			No coach/trainer meant less motivation	3 (n=1)
Never	24 (n=8)			Lack of interest	3 (n=1)

*Four of these participants were training with a sham device.

†All participants had continued using the device after initial 6 weeks of trial. RMT, respiratory muscle training.

Lung function

Contrary to previous literature,²² active RMT did not improve lung volumes compared with sham RMT. However, there was a strong positive correlation between P_{Imax} and IC, VC and PEF_c, which in this population with very low lung volumes and weak respiratory muscles may make a significant difference to breathlessness, the extent of atelectasis, effective mucus expectoration and the development of pneumonia. This association between increased P_{Imax} and lung function supports P_{Imax} being the strongest predictor of pneumonia in people with tetraplegia.⁶ Expiratory muscle training did not result in greater increases in P_{Emax} for the active group over the sham group. This may have been due to the high number of participants with complete cervical injuries (n=41) resulting in complete paralysis of the main expiratory muscles (internal intercostals and abdominals). With no innervated muscle to train, both active and sham complete groups only increased P_{Emax} by 1–3 cmH₂O. Innervated accessory muscles of expiration (pectorals, latissimus dorsi and serratus anterior) could have increased in strength, but participants were instructed not to brace their upper limbs while performing the assessments of lung function and P_{Emax}. For the group of participants with an incomplete injury (n=21), the small resistance of the sham tube and the manoeuvre of 36–60 exhalations twice daily may have been enough training to increase the P_{Emax} group mean by 8–10 cmH₂O in both the active and sham groups. This would indicate that the active training intensity was no more effective than sham training intensity. The possible reasons for the lack of significant changes in lung volume despite increases in P_{Imax} may be (1) long-term changes in chest wall stiffness, which have not reduced with training and (2) partial atelectasis, which prevents increases in lung volume. These hypotheses are yet to be tested.

Training

Recruitment ceased at 62 participants, rather than the target sample size of 80, due to funding but this had little effect on statistical precision because the sample size of 80 allowed for a 20% dropout rate. The active group trained at a 'moderate' to 'somewhat-severe' intensity (Borg score 3–4) which was the designated a priori perceived level of exertion. Training at a moderate level of effort is consistent with training intensities used for exercise groups and cardiovascular training. The protocol indicated that the maximal training intensity was capped at 80% weekly measured P_{Imax} or P_{Emax}. The training protocol was achieved by the active group,

but did not reach maximal. Active group participants commenced training at 30%/40% and progressed to maximal training pressures of 80%/83% baseline P_{Imax}/P_{Emax}, respectively. The sham group's actual training intensity was maintained between 8% and 13% baseline P_{Imax}/P_{Emax}, and their perceived training effort was a 'very-slight' to 'slight' intensity (Borg score 1–2). The work performed by the active group was significantly higher and supports the progressive training paradigm was suitable to achieve a training effect for inspiratory muscles, however ineffective for expiratory. Recent pilot studies investigating progressive RMT^{36,37} also showed this training paradigm to be feasible and effective in people with tetraplegia. The frequency of the training was supervised twice daily and labour intensive. Recent studies of RMT in healthy populations have indicated that three sessions of training per week were as effective as five times a week.³⁸ The intensive frequency of training in this trial may have resulted in the poor compliance when individuals were encouraged to continue training after 6 weeks.

One-year follow-up

The loss to follow-up after 1 year was high for this study, and only 62% of participants agreed to reassessment (figure 1). Only 48% people contacted had continued training independently after the initial 6 weeks. These participants were able to continue training with carer or family assistance or had sufficient hand function to train independently. However, despite being asked to record training frequency and intensity, participants found this too burdensome on top of the training and usual daily activities. Common reasons for not continuing RMT independently included lack of time, self-reported laziness, forgetfulness and poor hand function to use without carer assistance. Of those contacted, 84% reported benefits of RMT including increased strength, improved breathing and feeling better as they felt there was more air in their lungs. The 53% incidence of respiratory-related morbidity or mortality in the sham group is triple the incidence in the active group (14%), thus continued RMT regardless of the training intensity may reduce respiratory complications.

Strengths and limitations

This is the first study of RMT in tetraplegia with a high number of participants which are retained at the primary endpoint. The addition of examining QoL, respiratory symptoms and the number of respiratory complications are relevant clinical

implications for people with tetraplegia. The relatively high loss to follow-up after 1 year is a limitation as it may have contributed to a positive selection bias for the number of respiratory complications during this year. However, there were still differences in the QoL and respiratory symptom measures between active and sham groups. Some participants with higher near-normal initial P_{Imax} may not have trained with a high enough resistance as the training device is restricted in the maximal level of resistance it can provide. Despite this, P_{Imax} still increased for the active group. In practice, people with a higher initial P_{Imax} may benefit from a device which can deliver higher levels of resistance. This study has also highlighted, through the lack of independent training in the 1 year follow-up, that unless training is incorporated into routine care it is unlikely that people will be able to maintain a beneficial RMT regimen.

CONCLUSION

Progressive RMT over 6 weeks increases inspiratory muscle strength in people with tetraplegia, irrespective of time since injury and degree of injury completeness. This training paradigm improves respiratory symptom severity, reduces respiratory-related incidence, breathlessness at rest for those with recently acquired injuries and QoL for those people with a longer-standing injury. RMT should be implemented as a routine therapy for people with tetraplegia. The use of RMT to reduce respiratory-related mortality and morbidity has potential and could be further investigated after clinical roll out.

Acknowledgements The authors acknowledge Professor Rob Herbert for his statistical advice, Paraquad and Ferguson Lodge for their assistance with recruitment, Katlyn Anderson for data entry and also acknowledge all participants for their contributions to the study.

Contributors All authors contributed equally.

Funding This trial was supported by grants from the National Health and Medical Research Council (NHMRC) and The Prince of Wales Hospital Foundation (POWHF). The NHMRC and POWHF had no role in the design of the study nor the collection, analysis and interpretation of data or in writing the manuscript.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval New South Wales Government Health, South Eastern Sydney Local Health District, Human Research Ethics Committee, HREC Ref No: 12/192 (LNR/12/POWH/409). University of New South Wales, Human Research Ethics Committee, HREC Ref No: HC13388.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request from the corresponding author.

ORCID iD

Claire L Boswell-Ruys <http://orcid.org/0000-0003-4922-5262>

REFERENCES

- DeVivo MJ, Krause JS, Lammertse DP. Recent trends in mortality and causes of death among persons with spinal cord injury. *Arch Phys Med Rehabil* 1999;80:1411–9.
- McKinley WO, Jackson AB, Cardenas DD, et al. Long-Term medical complications after traumatic spinal cord injury: a regional model systems analysis. *Arch Phys Med Rehabil* 1999;80:1402–10.
- DeVivo MJ, Black KJ, Stover SL. Causes of death during the first 12 years after spinal cord injury. *Arch Phys Med Rehabil* 1993;74:248–54.
- Dore J. *The cost of severe SCI and traumatic brain injury in Victoria*. Trans Acc Comm, 2009.
- Savic G, DeVivo MJ, Frankel HL, et al. Causes of death after traumatic spinal cord injury—a 70-year British study. *Spinal Cord* 2017;55:891–7.
- Raeb AM, Krebs J, Perret C, et al. Maximum inspiratory pressure is a discriminator of pneumonia in individuals with spinal-cord injury. *Respir Care* 2016;61:1636–43.
- Illi SK, Held U, Frank I, et al. Effect of respiratory muscle training on exercise performance in healthy individuals: a systematic review and meta-analysis. *Sports Med* 2012;42:707–24.
- Cheah BC, Boland RA, Brodaty NE, et al. INSPIRATION – inspiratory muscle training in amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis* 2009;10:384–92.
- Lin K-H, Chuang C-C, Wu H-D, et al. Abdominal weight and inspiratory resistance: their immediate effects on inspiratory muscle functions during maximal voluntary breathing in chronic tetraplegic patients. *Arch Phys Med Rehabil* 1999;80:741–5.
- Liaw M-Y, Lin M-C, Cheng P-T, et al. Resistive inspiratory muscle training: its effectiveness in patients with acute complete cervical cord injury. *Arch Phys Med Rehabil* 2000;81:752–6.
- Loveridge B, Badour M, Dubo H. Ventilatory muscle endurance training in quadriplegia: effects on breathing pattern. *Paraplegia* 1989;27:329–39.
- Mueller G, Hopman M, Perret C. Comparison of respiratory muscle training methods in individuals with motor and sensory complete tetraplegia: a randomized controlled trial. *J Rehabil Med* 2013;45:248–53.
- Roth EJ, Stenson KW, Powley S, et al. Expiratory muscle training in spinal cord injury: a randomized controlled trial. *Arch Phys Med Rehabil* 2010;91:857–61.
- Rutchik A, Weissman AR, Almenoff PL, et al. Resistive inspiratory muscle training in subjects with chronic cervical spinal cord injury. *Arch Phys Med Rehabil* 1998;79:293–7.
- Wang T-G, Wang Y-H, Tang F-T, et al. Resistive inspiratory muscle training in sleep-disordered breathing of traumatic tetraplegia. *Arch Phys Med Rehabil* 2002;83:491–6.
- Ujil SG, Houtman S, Folgering HThM, et al. Training of the respiratory muscles in individuals with tetraplegia. *Spinal Cord* 1999;37:575–9.
- McCool FD, Mayewski RF, Shayne DS, et al. Intermittent positive pressure breathing in patients with respiratory muscle weakness. alterations in total respiratory system compliance. *Chest* 1986;90:546–52.
- Metcalf VA. Vital capacity and glossopharyngeal breathing in traumatic quadriplegia. *Phys Ther* 1966;46:835–8.
- Montero JC, Feldman DJ, Montero D. Effects of glossopharyngeal breathing on respiratory function after cervical cord transection. *Arch Phys Med Rehabil* 1967;48:650–3.
- Tamplin J, Baker FA, Grocke D, et al. Effect of singing on respiratory function, voice, and mood after quadriplegia: a randomized controlled trial. *Arch Phys Med Rehabil* 2013;94:426–34.
- Berlowitz DJ, Tamplin J. Respiratory muscle training for cervical spinal cord injury. *Cochrane Database Syst Rev* 2013;CD008507.
- Tamplin J, Berlowitz DJ. A systematic review and meta-analysis of the effects of respiratory muscle training on pulmonary function in tetraplegia. *Spinal Cord* 2014;52:175–80.
- Hill K, Jenkins SC, Philippe DL, et al. High-Intensity inspiratory muscle training in COPD. *Eur Respir J* 2006;27:1119–28.
- Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation. The St. George's respiratory questionnaire. *Am Rev Respir Dis* 1992;145:1321–7.
- Lee BB, Simpson JM, King MT, et al. The SF-36 walk-wheel: a simple modification of the SF-36 physical domain improves its responsiveness for measuring health status change in spinal cord injury. *Spinal Cord* 2009;47:50–5.
- Rabin R, Charro Fde, de Charro F. EQ-5D: a measure of health status from the EuroQol group. *Ann Med* 2001;33:337–43.
- Loveridge BM, Dubo H. Breathing pattern in chronic quadriplegia. *Arch Phys Med Rehabil* 1990;71:495–9.
- Fergusson D, et al. Post-Randomisation exclusions: the intention to treat principle and excluding patients from analysis. *BMJ* 2002;325:652–4.
- Mueller G, Groot S, Woude L, et al. Prediction models and development of an easy to use open-access tool for measuring lung function of individuals with motor complete spinal cord injury. *J Rehabil Med* 2012;44:642–7.
- Jackson AB, Grooms TE. Incidence of respiratory complications following spinal cord injury. *Arch Phys Med Rehabil* 1994;75:270–5.
- Winslow C, Bode RK, Felton D, et al. Impact of respiratory complications on length of stay and hospital costs in acute cervical spine injury. *Chest* 2002;121:1548–54.
- Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. *European Respiratory Journal* 2002;19:398–404.
- Borg GA. Psychophysical bases of perceived exertion. *Med Sci Sports Exerc* 1982;14:377–81.
- Arora S, Flower O, Murray NPS, et al. Respiratory care of patients with cervical spinal cord injury: a review. *Crit Care Resusc* 2012;14:64–73.
- Berlowitz DJ, Wadsworth B, Ross J. Respiratory problems and management in people with spinal cord injury. *Breathe* 2016;12:328–40.
- Boswell-Ruys CL, Lewis CRH, Gandevia SC, et al. Respiratory muscle training may improve respiratory function and obstructive sleep apnoea in people with cervical spinal cord injury. *Spinal Cord Ser Cases* 2015;1.
- McDonald T, Stiller K. Inspiratory muscle training is feasible and safe for patients with acute spinal cord injury. *J Spinal Cord Med* 2019;42:220–7.
- Lindholm P, Wylegala J, Pendergast DR, et al. Resistive respiratory muscle training improves and maintains endurance swimming performance in divers. *Undersea Hyperb Med* 2007;34:169–80.